The purpose of this study was to evaluate the frequency of detecting occult tumor cells in peripheral blood stem cell (PBSC) harvests and to determine the impact of infusing such cells on relapses after high-dose chemotherapy (HDC). Peripheral blood stem cell harvests from 223 patients with breast cancer were examined by an immunocytochemistry ( Nineteen patients who were infused with a mixture of ICC negative and untested PBSC harvests were excluded from analyses of relapse. The probabilities of relapse at 18 months for the 97 patients with stage II-III disease infused with ICC-negative and the 17 with ICC-positive PBSC were 0.19 and 0.13, respectively (P = 0.48). The probabilities of relapse at 18 months for patients achieving a CR or a CR in non-bone sites and improvement in bone lesions were 0.55 for the ICCnegative group (n = 30) and 0.45 for the ICC-positive group (n = 11) (P = 0.60). It was concluded that occult tumor cells were detected by ICC in PBSC harvests from a relatively small fraction of women with breast cancer, but were not associated with a significant increase in the probability of early relapse or progression when infused after HDC.
Immunocytochemical (ICC) techniques detect breast carcinoma cells in bone marrow (BM) and peripheral blood stem cells (PBSC) from patients with breast cancer who have negative histological examinations and have been utilized to evaluate patients undergoing high-dose chemotherapy (HDC) followed by autologous stem cell infusion. [1] [2] [3] [4] Previously reported seeding experiments, using cultured tumor cells, have established the sensitivity of tumor cell detection of ICC methodology to be one tumor cell per 5.0 × 10 5 hematopoietic cells. 5 The presence of tumor cells in BM of patients with breast cancer, as detected by ICC or polymerase chain reaction (PCR), has been predictive of adverse outcomes in most, [6] [7] [8] [9] [10] [11] but not all studies. 12, 13 However, the clinical relevance of occult tumor cells in peripheral blood or PBSC harvests has not been extensively evaluated. 1, 8, 11, [14] [15] [16] Blood-borne tumor cells have been shown to possess the capacity for clonogenic growth in vitro 1, 8 and could contribute to or cause post-transplant relapse. 17, 18 The contribution of infused tumor cells to relapse or progression after HDC and PBSC support in patients with breast cancer has not been determined.
In order to design clinical studies to evaluate the effectiveness of techniques to remove putative tumor cells from the graft it will be important to determine if infused tumor cells in the graft contribute significantly to treatment failure. One simple comparison would be to compare the outcomes for patients infused with a graft known to contain occult tumor cells with those infused with a graft free of tumor cells. The current study evaluated the frequency of detecting tumor cells, as measured by ICC, in PBSC collections from patients with breast cancer and compared the clinical outcomes of patients infused with PBSC containing or not containing tumor cells.
Patients and methods

Patient population
One hundred and twenty-two patients with stage II-III and 101 with stage IV breast cancer underwent mobilization and PBSC harvest between August 1992 and May 1995 and were entered on a prospective trial to evaluate an ICC method of detecting tumor cells in PBSC harvests. All patients signed a protocol-specific informed consent approved by the institutional review board of the hospital where the therapy was administered. All patients were informed that no clinical decisions would be made on the basis of results of ICC tests.
Treatment centers
Patients were treated in outpatient facilities associated with 27 community cancer centers by 96 practising oncologists affiliated with the Clinical Trials Division of Response Oncology, Inc, Memphis, TN (listed at the end of the manuscript).
Staging of patients
All patients with stage II-III disease were staged using standard procedures. 19 All patients with stage IV disease were restaged 2-3 weeks prior to mobilization of PBSC. 20 
Induction chemotherapy
Stage II-III disease: One hundred and two patients with stage II-III disease received 4-6 cycles of standard-dose adjuvant chemotherapy which was initiated a median of 79 days prior to mobilization of PBSC. 19 Twenty patients with locally advanced disease (stage IIIA or B) were entered on a trial of neoadjuvant therapy and all received 4-6 cycles of standard-dose adjuvant chemotherapy before surgery. Mobilization of PBSC with chemotherapy and granulocyte colony-stimulating factor (G-CSF) was carried out before (n = 13) or after surgery (n = 7). High-dose chemotherapy and PBSC infusion were followed by radiation therapy in all patients and hormonal therapy for patients who were estrogen/progesterone receptor positive. 21 Stage IV disease: Ninety-one of 101 patients (90%) were entered on study after initial induction chemotherapy and 10 after salvage chemotherapy for failure of induction or relapse following induction.
Mobilization of peripheral blood stem cells
Peripheral blood stem cells were collected following administration of the chemotherapy and G-CSF (filgrastim; Amgen, Thousand Oaks, CA, USA) or G-CSF alone regimens outlined in Tables 1 and 2. 22 Mobilization regimens were dictated by protocols in place at the time of treatment. [23] [24] [25] [26] The 30 patients with stage IV disease who had PBSC mobilized with G-CSF alone were randomized to received 10 g (n = 6), 20 g (n = 17) or 30 g (n = 7) /kg/day. 26 Granulocyte colony-stimulating factor, 6 g/ kg/day, was administered subcutaneously beginning 1 day after completion of chemotherapy and continued until discontinuation of apheresis.
Collection, cryopreservation and infusion of peripheral blood stem cells: Following the administration of chemotherapy and G-CSF, apheresis was performed daily with a continuous flow centrifuge (Fenwal CS-3000 Plus, Baxter, Deerfield, IL, USA) beginning when the white blood count reached 1 × 10 9 /l with the goal of collecting у2.5 × 10 6
CD34
+ cells/kg/patient. In patients receiving G-CSF alone, PBSC harvests were initiated on day 5 of G-CSF administration. An aliquot was taken from the entire collection of PBSC on a day of apheresis for determination of CD34 + cell content 22 and for ICC assay as described below. After sampling, the PBSC harvest was placed in one or more bags and cryopreserved as previously described. 23 Peripheral blood stem cells were thawed and infused 48-72 h after the last dose of HDC and the day of infusion was designated day 0. One hundred and thirty-five patients (61%) received all and 88 (39%), with an excess number of CD34 19 All patients received G-CSF, 6 g/kg/day, from the day of PBSC infusion (day 0) until the absolute neutrophil count was Ͼ0.5 × 10 9 /l for 3 consecutive days. 22 The median interval from initiation of mobilization chemotherapy to the administration of HDC was 35 days (range 21-57) for 102 patients receiving adjuvant therapy and 48 days (range 28-99) for the 20 patients receiving neoadjuvant therapy.
Stage IV disease:
Fifty patients (49%) received CTCb as described above and 51 (50%) received a regimen of busulfan (12 mg/kg), melphalan 100 mg/m 2 and thiotepa 500 mg/m 2 (BuMelTT). 27, 28 All received G-CSF after PBSC infusion as described above. The median interval from initiation of mobilization chemotherapy or G-CSF administration to HDC was 34 days (range 8-133).
Measurement of tumor cells
An aliquot (3-5 ml) of a PBSC harvest, containing a minimum of 1 × 10 7 cells/ml, was placed in sterile sodium heparin tubes and shipped at room temperature overnight to BIS Laboratories (Reseda, CA, USA). The ICC staining procedure for the detection of tumor cells has been described. 1, 4, 29 Briefly, mononuclear cells were incubated with a cocktail of immunoglobulin G murine monoclonal antibodies directed against breast or glandular epithelial antigens (SB-6; Accurate Chemical, Westbury, NY, USA; SB-3; CalTag, San Francisco, CA, USA; and TFS-2; Biodesign, Kennebunkport, ME, USA). Cytospin preparations were then immunostained using the a streptavidin immunoperoxidase kit (Zymed, San Francisco, CA, USA).
A cell was considered ICC-positive when immunostaining was observed on at least 75% of the cell membrane and cytoplasm and morphology were consistent with a malignant cell. The number of tumor cells per ICC-stained specimen was recorded by two blinded observers. Discrepancies in ICC results were resolved by additional immunostaining experiments and joint consultation.
The results were classified into the following categories. A negative sample = evaluation of у10 5 cells without the presence of immunostained cells; a positive sample = the presence of immunostained cells with morphology consistent with malignancy; a suspicious sample = the presence of immunostained cells with either weak immunostaining or morphology not fully consistent with malignancy; an invalid or indeterminate sample = evaluation of Ͻ10 5 cells or poor morphology of the cells prohibiting accurate visual analysis. In this report suspicious tests were considered to be positive.
Treatment after high-dose chemotherapy and PBSC infusion
Ninety-seven of 122 patients (80%) with stage II-III disease received local-regional radiation therapy a median of 60 days (range 26-598) after HDC.
Fifty-two of 122 patients with stage II-III disease who were estrogen and/or progesterone receptor positive were given tamoxifen 10 mg, orally, twice a day or megace 40 mg, orally, four times a day following recovery from HDC for a minimum of 2 years or until disease progression.
Clinical and statistical evaluations:
All patients were restaged 6-8 weeks after PBSC infusion and responses in stage IV patients were categorized using standard criteria. Patients who achieved a CR in non-bone sites and improvement in bone lesions were classified as PR*. 30 All data were collected using a custom designed distributed data system, reviewed at a central clinical trials center (Response Oncology, Memphis, TN, USA) and analyzed using the SAS system (SAS institute, Cary, NC, USA). Time to relapse or progression was calculated from the day of PBSC infusion and patients without relapse or progression were censored on the day of last contact with the date of longest follow-up being 8 August 1997. The probabilities of relapse or progression were calculated using the method of Kaplan and Meier and compared using a log-rank test. 31 Proportions were tested using 2 or Fisher's exact method, as
appropriate. Quantitative variables were tested using the Wilcoxon rank sum test.
Results
Patient characteristics
Stage II-III disease: Patients with ICC-positive PBSC harvests underwent a mean of 2.5 aphereses and had a mean of 2.5 ICC tests performed as compared to 2.2 (P = 0.16) and 2.1 (P = 0.08), respectively, for patients with ICC negative tests. There were no other differences in pretreatment characteristics, mobilization regimens or treatment after HDC between patients who had ICC positive or negative PBSC collected.
Stage IV disease:
Characteristics for the 101 patients with stage IV disease are shown in Table 1 .
Patients with ICC-positive tests (n = 24) presented at initial diagnosis with more lymph nodes involved with tumor (P = 0.01) and were more likely to have presented with more advanced disease (stage III-IV) at diagnosis than patients who were ICC negative (P = 0.03).
Thirty patients (30%) with stage IV disease had PBSC mobilized with G-CSF alone and 71 (71%) with chemotherapy and G-CSF. Twenty-one of 77 ICC-negative patients (27%) had PBSC mobilized with G-CSF alone as compared to 9/24 (38%) of the ICC-positive patients (P = 0.34).
Patients with ICC-positive PBSC harvests underwent more aphereses (P = 0.006), had more ICC tests performed (P Ͻ 0.001) and were infused with less CD34
+ cells/kg (P = 0.01) than patients who were ICC negative.
Results of ICC testing of PBSC
All patients had at least one PBSC harvest tested by ICC; 114/122 (93%) patients with stage II-III disease and 88/101 (87%) patients with stage IV disease had all harvests tested. Five hundred and eighty-one of 619 PBSC harvests (94%) were tested by ICC.
In patients with stage II-III disease, three PBSC harvests were suspicious and 19 were positive; the number of tumor cells detected/10 5 cells/harvest was 1 (n = 11), 2 (n = 4), 3 (n = 2), 4 (n = 1) and 5 (n = 1). In patients with stage IV disease 10 PBSC harvests were suspicious and 21 were positive; the number of tumor cells detected/10 5 cells/harvest was 1 (n = 13), 2 (n = 6), 3 (n = 1) and 5 (n = 1).
Eighteen per cent of all patients had positive ICC tests; 14% in patients with stage II-III disease and 24% in patients with stage IV disease (P = 0.06) ( Table 3 ). The frequency of positive ICC PBSC harvests was 9%; 8% from patients with stage II-III disease and 10% from patients with stage IV disease (P = 0.69).
Patients with stage II-III disease had a median of two PBSC harvests tested (range 1-7) vs 3 (range 1-11) for patients with stage IV disease (P Ͻ 0.001). Patients with stage IV disease who were in the ICC-negative group had a median of two PBSC harvests tested as compared to four for patients in the ICC-positive group (P Ͻ 0.001) ( Table 1 ). Eleven per cent of patients who had 1-2 PBSC harvests tested had positive ICC tests compared to 32% of patients who had у3 harvests tested (P Ͻ 0.001). Seven per cent of PBSC harvests from patients who had 1-2 harvests tested were positive compared to 11% from patients who had у3 harvests tested (P = 0.06). Detailed results of similar data for patients with stage II-III and stage IV patients are shown in Table 2 .
Nine of 30 patients (30%) with stage IV disease who had PBSC mobilized with G-CSF alone had ICC-positive tests compared to 15 of 71 (21%) who had PBSC mobilized with chemotherapy and G-CSF (P = 0.34). Eighteen of 204 PBSC harvests (8.8%) collected following chemotherapy and G-CSF were ICC positive compared to 13/111 PBSC harvests (11.7%) following G-CSF alone (P = 0.41).
Fifty-seven of 101 patients (56%) with stage IV disease had bone involvement and 14 of these (24%) had positive ICC tests of PBSC compared to 10 of 44 patients (23%) without bone involvement (P = 0.80). Sixteen of 168 PBSC harvests (10%) from patients with bone involvement were positive compared to 15/147 (10%) from patients without bone involvement (P = 0.84). Twenty-one patients had у5 bone lesions and seven of these (33%) had positive ICC tests compared to seven of 36 (19%) with Ͻ5 bone lesions (P = 0.26). Seven of 78 PBSC harvests (9%) from patients with у5 bone lesions were ICC positive compared to 24 of 237 harvests (10%) from patients with Ͻ5 bone lesions (P = 0.77).
Probability or relapse or progression
Stage II-III breast cancer: The eight patients who received a mixture of ICC-negative and untested PBSC harvests were excluded from these analyses. There were no treatment-related deaths in the 114 patients with stage II-III disease. Four of 17 patients (24%) who were infused with ICC-positive PBSC relapsed; two in bone only on days 325 and 701, one in supraclavicular lymph nodes only on day 525 and one in liver on day 879. Thirty of 97 patients (31%) who received PBSC that were ICC negative relapsed in bone only (n = 9), bone plus other sites (n = 6), viscera (n = 9), brain (n = 3), local soft tissue and/or lymph nodes (n = 2) and breast (n = 1) at a median of 521 days (range 60-795). With a median follow-up of 30 months (range 19-42), the probabilities of relapse at 18 months for the 97 patients with stage II-III disease who received ICC-negative and the 17 who received ICC-positive PBSC were 0.19 and 0.13, respectively, (P = 0.48) as shown in Figure 1 .
Stage IV breast cancer:
Eleven patients who received a mixture of ICC negative and untested PBSC harvests were excluded from these analyses. Five of 90 patients (6%) died of treatment-related causes before day 100, all in the ICCnegative group. Following HDC, 33 of 90 patients (37%) were in CR; 25 of 66 ICC-negative patients (38%) and eight of 24 ICC-positive patients (33%). Eight patients with bone disease were in CR in non-bone sites and had significant improvement in bone lesions after HDC and were classified as PR*. 30 After HDC, 41 of 90 patients (46%) were in CR/PR*; 30 of 66 (45%) in the ICC-negative group and 11 of 24 (46%) in the ICC-positive group.
The probabilities of relapse or progression at 18 months for the 66 patients with stage IV disease who received ICCnegative and the 24 who received ICC-positive PBSC were 0.69 and 0.69, respectively (P = 0.72). The probabilities of relapse for the 41 patients who achieved a CR/PR* and of progression for 49 patients not achieving CR/PR* were 0.53 and 0.84, respectively (P Ͻ 0.001). The probabilities of relapse at 18 months for patients achieving a CR/PR* were 0.55 for the ICC-negative group (n = 30) and 0.45 for the ICC-positive group (n = 11) as shown in Figure 2 (P = 0.60).
Discussion
Here, patients with suspicious tests were included with those having positive tests because of the high frequency of positive clonogenic assays observed in this group of patients. Furthermore, when the data were analyzed excluding suspicious tests there was no impact on the overall conclusions. Of 223 patients with breast cancer, 14% of those with stage II-III disease and 24% of those with stage IV disease (P = 0.06), had PBSC harvests that were positive for breast cancer cells by ICC. The incidence of positive harvests was 8% for patients with stage II-III disease and 10% for patients with stage IV disease (P = 0.69).
More patients with stage IV breast cancer had positive ICC tests than patients with stage II-III disease (P = 0.06). However, those with stage IV disease had an average of three PBSC harvests tested by ICC compared to two for patients with stage II-III disease (P Ͻ 0.001). Patients who had у3 PBSC harvests tested by ICC were three times more likely to have a positive test compared to patients having р2 PBSC harvests tested. Among patients with stage IV disease, those who were ICC positive had a median of four PBSC harvests evaluated by ICC as compared to two harvests in patients with ICC negative tests (P Ͻ 0.001). These observations, taken together, suggest that the increased incidence of ICC-positive tests in patients with stage IV disease and/or in patients who were 'poor mobilizers' was predominantly due to the increased number of ICC tests performed. This suggests that testing of more PBSC harvests or more cells/harvest would increase the incidence of patients with positive tests.
In a study by Ross et al, It has been reported that mobilization of PBSC with a growth factor alone results in a higher frequency of harvests containing occult tumor than following chemotherapy and a growth factor. 11 In the current study, all patients with stage II-III disease had PBSC mobilized with chemotherapy and G-CSF and the frequency of ICC-positive harvests was low (8%). In patients with stage IV disease, 30 of 101 patients (30%) had PBSC mobilized with G-CSF alone. 26 The frequency of patients with ICC-positive PBSC harvests was 30% following mobilization with G-CSF alone and 21% following chemotherapy and G-CSF (P = 0.34). Twelve per cent of PBSC harvests were ICCpositive following mobilization with G-CSF alone and 9% following chemotherapy and G-CSF (P = 0.41). These results are similar to those reported by Passos-Coelho et al 14 where differences in occult tumor contamination between PBSC harvests following mobilization with a growth factor alone or following chemotherapy plus a growth factor were not observed. However, larger numbers of patients could uncover differences.
The effect of infusing ICC-positive PBSC was evaluated in patients with stage II-III disease and in patients with stage IV disease who achieved a CR or PR*. The probabilities of relapse at 18 months for patients receiving ICCpositive or ICC-negative PBSC were not different, as shown in Figures 1 and 2 . Although there were no trends for a higher relapse rate following infusion of ICC-positive PBSC it is possible, but unlikely, that further follow-up could reveal differences.
These results suggest that the re-infusion of occult tumor cells in PBSC, as detected by ICC, do not contribute significantly to relapse following HDC in patients with breast cancer. There are several possible explanations for these observations: the number of tumor cells may be too few to cause relapses, all occult tumor cells may not be clonogenic in vivo, freezing and thawing could affect the number and clonogenicity of tumor cells, the immune system of the patient could eliminate the relatively small number of tumor cells infused and/or ultrasensitive ICC or other testing methods will need to be employed to reduce the number of possible false negative results. Any one or a combination of these mechanisms could explain the apparent lack of effect of infused tumor cells on relapse. Irrespective of the mechanisms involved, these observations have implications for the design of clinical trials to evaluate the benefit of purging of tumor cells from PBSC harvests.
There are in vitro studies documenting the efficacy of purging BM of PBSC of breast cancer cells. 3, 4, [32] [33] [34] However, there have been no prospective randomized trials to determine if these techniques diminish the probability of relapse or progression after HDC and BM or PBSC infusion. Randomized clinical trials designed to evaluate an effect of purging on relapse or progression will be difficult, if not impossible, to perform because available HDC regimens do not eradicate endogenous disease in the majority of patients with stage IV breast cancer. The problem could theoretically be reduced by evaluating only patients who are in CR after HDC and PBSC infusion where the probability of relapse is significantly lower than in patients with residual disease. 19, 20, 30, 35 In the current study, only 41 of 90 evaluable patients (47%) with stage IV disease were in CR/PR* after HDC and the probabilities of relapse were 0.52 for the ICC-negative group (n = 30) and 0.45 for the ICC-positive group (n = 11) as shown in Figure 2 . Although these numbers are relatively small there is no trend toward an increase in relapse in patients infused with ICC-positive PBSC. This suggests that randomized trials to evaluate the potential beneficial effects of purging would require large numbers of patients, even if limited to patients who were in CR or PR* and had PBSC harvested that were ICCpositive.
Only two other studies have attempted to correlate ICC testing of PBSC with outcome of patients with stage IV breast cancer receiving HDC with PBSC support. 15, 16 Ybanez et al, 15 in a study involving 41 patients with stage IV breast cancer, found no difference in outcome between nine patients infused with ICC-positive PBSC, BM or both and 25 infused with ICC-negative grafts. Stadtmauer et al 16 reported no differences in outcome between patients receiving ICC-positive or -negative PBSC harvests, but the total number of patients studied was only 27. However, in a larger study, ICC-positive or -negative PBSC products did correlate with clinical outcome when paired with ICC marrow analysis. 36 These results indicate that studies with large numbers of patients may be needed for more meaningful analysis of occult tumor burden as a prognostic factor for outcome of patients with metastatic breast cancer.
In patients with stage II-III breast cancer the probability of relapse was significantly less than in patients with stage IV disease. In order to detect an effect of purging in this setting a significant fraction of the relapses would have to be due to infused tumor cells. At the present time, there is no evidence that this is the case. In the current study only 3/17 patients (18%) infused with ICC-positive PBSC have relapsed as compared to 23% in the ICC-negative group. However, longer follow-up may be required to determine whether or not there will ultimately be differences between these two groups.
Even if a more sensitive test for occult tumor cells were more predictive for relapse this finding would not necessarily prove that infused tumor cells cause relapses as a more sensitive test may identify patients with a greater tumor burden and/or more resistant disease at a higher risk of relapse from residual endogenous tumor. However, once relapses from endogenous residual tumors are eliminated tests for occult tumor cells in PBSC might be more predictive of relapse.
In summary, detection of occult tumor cells by ICC in PBSC harvests that were infused into patients receiving HDC for breast cancer was not associated with an increase in the probability of early relapse.
Note added in proof
With a further 8 months of follow-up there have been an additional four relapses among the 155 patients with breast cancer infused with ICC-positive or -negative PBSC. Two relapses were in patients with stage II-III disease, one infused with ICC-negative and one infused with ICC-positive PBSC. Two relapses occurred in patients with metastatic disease; both infused with ICC-negative PBSC. Thus, with a median follow-up of 36 months and a minimum follow-up of over 2 years there are no differences in relapses between recipients of ICC-negative or -positive PBSC.
